# Head to Head Study of Anti-VEGF Treatment.

> **NCT02577107** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Age-related Macular Degeneration

## Interventions

- **DRUG:** ranibizumab
- **DRUG:** Conbercept

## Key facts

- **NCT ID:** NCT02577107
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-13
- **Primary completion:** 2016-07-09
- **Final completion:** 2016-07-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577107, "Head to Head Study of Anti-VEGF Treatment.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02577107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*